伊巴利珠单抗和fostemsaver在大量预先治疗的hiv感染患者中的应用

Q3 Medicine
Niccolò Riccardi, Marco Berruti, Filippo Del Puente, Lucia Taramasso, Antonio Di Biagio
{"title":"伊巴利珠单抗和fostemsaver在大量预先治疗的hiv感染患者中的应用","authors":"Niccolò Riccardi,&nbsp;Marco Berruti,&nbsp;Filippo Del Puente,&nbsp;Lucia Taramasso,&nbsp;Antonio Di Biagio","doi":"10.2174/1574891X13666181031120019","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Heavily treated HIV-1 infected patients may have limited therapeutic alternatives. In order to ensure sustained HIV-RNA suppression in these patients and to improve current antiretroviral treatment regimens in the fight against multi-drug resistant strains, new drugs are needed. Recently, two new drugs among the new generation of entry inhibitors showed promises for both their characteristics and mechanism of action.</p><p><strong>Objective: </strong>To outline ibalizumab (Patent: US20120121597A1) and fostemsavir (Patent: US8871771) future applications in people living with multi-drug resistant HIV with few remaining treatment options.</p><p><strong>Methods: </strong>We analysed the available literature and data from ongoing clinical trials about ibalizumab and fostemsavir.</p><p><strong>Results: </strong>Ibalizumab is a new humanized monoclonal antibody. It acts as post-attachment inhibitor by binding CD4 2nd domain of T lymphocyte and preventing HIV connection to CCR5 or CXCR4 and has been recently approved by Food and Drug Administration in the United States of America as a new intravenous antiretroviral agent for heavily treated HIV adults with multi -drug resistant infection. Fostemsavir (formerly BMS-663068), the oral prodrug of temsavir, is another attachment inhibitor. It acts by preventing the viral connection to CD4 by binding gp120. This drug showed encouraging results in heavily treated patients as add-on agent to current antiretroviral regimens, in particular for subtype B virus. It is currently being investigated in a phase 3, two-cohort (randomized and non-randomized), trial.</p><p><strong>Conclusion: </strong>The history of ibalizumab and fostemsavir will be written in next years. Continuing the research will be crucial to obtain evidence based guidelines for the management of heavily treated HIV-1 infected patients with limited therapeutic options.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.\",\"authors\":\"Niccolò Riccardi,&nbsp;Marco Berruti,&nbsp;Filippo Del Puente,&nbsp;Lucia Taramasso,&nbsp;Antonio Di Biagio\",\"doi\":\"10.2174/1574891X13666181031120019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Heavily treated HIV-1 infected patients may have limited therapeutic alternatives. In order to ensure sustained HIV-RNA suppression in these patients and to improve current antiretroviral treatment regimens in the fight against multi-drug resistant strains, new drugs are needed. Recently, two new drugs among the new generation of entry inhibitors showed promises for both their characteristics and mechanism of action.</p><p><strong>Objective: </strong>To outline ibalizumab (Patent: US20120121597A1) and fostemsavir (Patent: US8871771) future applications in people living with multi-drug resistant HIV with few remaining treatment options.</p><p><strong>Methods: </strong>We analysed the available literature and data from ongoing clinical trials about ibalizumab and fostemsavir.</p><p><strong>Results: </strong>Ibalizumab is a new humanized monoclonal antibody. It acts as post-attachment inhibitor by binding CD4 2nd domain of T lymphocyte and preventing HIV connection to CCR5 or CXCR4 and has been recently approved by Food and Drug Administration in the United States of America as a new intravenous antiretroviral agent for heavily treated HIV adults with multi -drug resistant infection. Fostemsavir (formerly BMS-663068), the oral prodrug of temsavir, is another attachment inhibitor. It acts by preventing the viral connection to CD4 by binding gp120. This drug showed encouraging results in heavily treated patients as add-on agent to current antiretroviral regimens, in particular for subtype B virus. It is currently being investigated in a phase 3, two-cohort (randomized and non-randomized), trial.</p><p><strong>Conclusion: </strong>The history of ibalizumab and fostemsavir will be written in next years. Continuing the research will be crucial to obtain evidence based guidelines for the management of heavily treated HIV-1 infected patients with limited therapeutic options.</p>\",\"PeriodicalId\":20909,\"journal\":{\"name\":\"Recent patents on anti-infective drug discovery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent patents on anti-infective drug discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1574891X13666181031120019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on anti-infective drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574891X13666181031120019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

背景:大量治疗的HIV-1感染患者可能有有限的治疗选择。为了确保在这些患者中持续抑制HIV-RNA,并在与多重耐药菌株的斗争中改进目前的抗逆转录病毒治疗方案,需要新的药物。近年来,在新一代进入抑制剂中,有两种新药在其特性和作用机制方面都显示出良好的前景。目的:概述ibalizumab(专利:US20120121597A1)和fostemsavir(专利:US8871771)在剩余治疗方案很少的多药耐药HIV患者中的未来应用。方法:我们分析了有关伊巴利珠单抗和fostemsaver的现有文献和正在进行的临床试验数据。结果:Ibalizumab是一种新的人源化单克隆抗体。它通过结合T淋巴细胞的CD4 2结构域作为附着后抑制剂,防止HIV与CCR5或CXCR4的连接,最近被美国食品和药物管理局批准作为一种新的静脉内抗逆转录病毒药物,用于治疗多重耐药感染的重度治疗HIV成人。Fostemsavir(原BMS-663068)是temsavir的口服前药,是另一种附着抑制剂。它的作用是通过结合gp120阻止病毒与CD4的连接。这种药物作为当前抗逆转录病毒治疗方案的附加药物,在重度治疗患者中显示出令人鼓舞的结果,特别是对B型病毒。目前正在进行一项3期双队列(随机和非随机)试验。结论:伊巴利珠单抗和fostemsavr的历史将在未来几年书写。继续进行这项研究对于获得以证据为基础的指导方针,以管理治疗方案有限的大量治疗的HIV-1感染患者至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.

Background: Heavily treated HIV-1 infected patients may have limited therapeutic alternatives. In order to ensure sustained HIV-RNA suppression in these patients and to improve current antiretroviral treatment regimens in the fight against multi-drug resistant strains, new drugs are needed. Recently, two new drugs among the new generation of entry inhibitors showed promises for both their characteristics and mechanism of action.

Objective: To outline ibalizumab (Patent: US20120121597A1) and fostemsavir (Patent: US8871771) future applications in people living with multi-drug resistant HIV with few remaining treatment options.

Methods: We analysed the available literature and data from ongoing clinical trials about ibalizumab and fostemsavir.

Results: Ibalizumab is a new humanized monoclonal antibody. It acts as post-attachment inhibitor by binding CD4 2nd domain of T lymphocyte and preventing HIV connection to CCR5 or CXCR4 and has been recently approved by Food and Drug Administration in the United States of America as a new intravenous antiretroviral agent for heavily treated HIV adults with multi -drug resistant infection. Fostemsavir (formerly BMS-663068), the oral prodrug of temsavir, is another attachment inhibitor. It acts by preventing the viral connection to CD4 by binding gp120. This drug showed encouraging results in heavily treated patients as add-on agent to current antiretroviral regimens, in particular for subtype B virus. It is currently being investigated in a phase 3, two-cohort (randomized and non-randomized), trial.

Conclusion: The history of ibalizumab and fostemsavir will be written in next years. Continuing the research will be crucial to obtain evidence based guidelines for the management of heavily treated HIV-1 infected patients with limited therapeutic options.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Recent patents on anti-infective drug discovery
Recent patents on anti-infective drug discovery Medicine-Pharmacology (medical)
CiteScore
2.40
自引率
0.00%
发文量
1
期刊介绍: Recent Patents on Anti-Infective Drug Discovery publishes review articles on recent patents in the field of anti-infective drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-infective drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-infective drug design and discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信